Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status

TRANSLATIONAL RELEVANCE: Evaluation of targeted therapies is urgently needed for the majority of patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) who progress after immunochemotherapy. Erlotinib, a targeted inhibitor of epidermal growth factor receptor pathway, lacks...

Descripción completa

Detalles Bibliográficos
Autores principales: Porosnicu, Mercedes, O’Brien Cox, Anderson, Waltonen, Joshua D., Bunch, Paul M., D’Agostino, Ralph, Lycan, Thomas W., Taylor, Richard, Williams, Dan W., Chen, Xiaofei, Shukla, Kirtikar, Kouri, Brian E., Walker, Tiffany, Kucera, Gregory, Patwa, Hafiz S., Sullivan, Christopher A., Browne, J. Dale, Furdui, Cristina M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468744/
https://www.ncbi.nlm.nih.gov/pubmed/36110959
http://dx.doi.org/10.3389/fonc.2022.939118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468744/
https://www.ncbi.nlm.nih.gov/pubmed/36110959
http://dx.doi.org/10.3389/fonc.2022.939118

Ejemplares similares